Last reviewed · How we verify
NCT03065790
Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide
trial testing 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) in Non-Hodgkin Lymphoma in 1 participant. Terminated before completion.
28 April 2021
Quick facts
| Lead sponsor | Abramson Cancer Center at Penn Medicine |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 1 |
| Start date | 6 February 2017 |
| Primary completion | 28 April 2021 |
| Estimated completion | 28 April 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) — full drug profile →
Conditions studied
- Non-Hodgkin Lymphoma — all drugs for Non-Hodgkin Lymphoma →
Sponsor
Abramson Cancer Center at Penn Medicine — full company profile →
Who can join
18 and older, any sex, with Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03065790
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT07284927 — Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies · Phase 1 · recruiting
- NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
- NCT07260812 — KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · Phase 1 · recruiting
- NCT06915246 — A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma · Phase 2 · recruiting
Other Abramson Cancer Center at Penn Medicine trials
Trials by the same sponsor.
- NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
- NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
- NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03065790 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
- Last refreshed: 4 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03065790.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing